

CHAPTER ONE: INTRODUCTION	1
STUDY OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
INTENDED AUDIENCE.....	2
SCOPE OF THE STUDY.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
ABOUT THE AUTHOR.....	3
RELATED BCC REPORTS.....	3
BCC ONLINE SERVICES.....	4
DISCLAIMER.....	4
CHAPTER TWO: SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL SALES FOR DRUG DELIVERY</i> <i>PRODUCTS, THROUGH 2014 (\$ BILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL SALES FOR DRUG DELIVERY</i> <i>PRODUCTS, 2007-2014 (\$ BILLIONS)</i>	6
CHAPTER THREE: OVERVIEW.....	7
DEFINITIONS.....	7
NEED FOR THE DOSAGE FORMS.....	7
CLASSIFICATION OF DOSAGE FORMS ACCORDING TO PHYSICAL PROPERTIES.....	8
GASEOUS DOSAGE FORMS.....	8
<i>TABLE 1 GASEOUS DOSAGE FORMS, ADVANTAGES AND</i> <i>DISADVANTAGES</i>	9
LIQUID DOSAGE FORMS.....	9
<i>TABLE 2 LIQUID DOSAGE FORMS, ADVANTAGES AND</i> <i>DISADVANTAGES</i>	9
SEMISOLID DOSAGE FORMS.....	10
<i>TABLE 3 SEMISOLID DOSAGE FORMS, ADVANTAGES AND</i> <i>DISADVANTAGES</i>	10
SOLID DOSAGE FORMS.....	10
<i>TABLE 4 SOLID DOSAGE FORMS, ADVANTAGES AND</i> <i>DISADVANTAGES</i>	11
CLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATION.....	11
TOPICAL DRUG DELIVERY.....	12
<i>TABLE 5 TOPICAL DRUG DELIVERY, ADVANTAGES AND</i> <i>DISADVANTAGES</i>	12
ORAL DRUG DELIVERY.....	13
<i>TABLE 6 ORAL DRUG DELIVERY, ADVANTAGES AND</i> <i>DISADVANTAGES</i>	13
INJECTABLE OR PARENTERAL DRUG DELIVERY.....	13

<i>TABLE 7 INJECTABLE OR PARENTERAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES</i>	14
RECTAL DRUG DELIVERY	14
<i>TABLE 8 RECTAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES</i>	15
NASAL DRUG DELIVERY	15
<i>TABLE 9 NASAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES</i>	15
<i>TABLE 9 (CONTINUED)</i>	16
VAGINAL DRUG DELIVERY	16
<i>TABLE 10 VAGINAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES</i>	16
OCULAR DRUG DELIVERY	17
<i>TABLE 11 OCULAR DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES</i>	17
PULMONARY DRUG DELIVERY.....	17
<i>TABLE 12 PULMONARY DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES</i>	18
CLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGY	18
SUSTAINED-RELEASE DRUG DELIVERY	18
<i>TABLE 13 SUSTAINED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES</i>	19
DELAYED-RELEASE DRUG DELIVERY	19
<i>TABLE 14 DELAYED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES</i>	19
PRODRUGS.....	20
<i>TABLE 15 PRODRUGS, ADVANTAGES AND DISADVANTAGES</i>	20
IMPLANTS AND IUDS	20
<i>TABLE 16 IMPLANTS AND IUDS, ADVANTAGES AND DISADVANTAGES</i>	21
TARGETED DRUG DELIVERY.....	21
Nanoparticles.....	21
Liposomes	22
<i>TABLE 17 LIPOSOMES, ADVANTAGES AND DISADVANTAGES</i>	22
Polymers.....	22
<i>TABLE 18 POLYMERS, ADVANTAGES AND DISADVANTAGES</i>	23
Monoclonal Antibodies	23
<i>TABLE 19 MONOCLONAL ANTIBODIES, ADVANTAGES AND DISADVANTAGES</i>	24
PEGylation.....	24
<i>TABLE 20 PEGYLATION, ADVANTAGES AND DISADVANTAGES</i>	24
CHAPTER FOUR: REGULATORY ISSUES.....	25

<i>TABLE 21 FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMS (2005 TO FEB 2009)</i>	25
<i>TABLE 21 (CONTINUED)</i>	26
<i>TABLE 21 (CONTINUED)</i>	27
<i>TABLE 22 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR, 2005- FEB. 2009</i>	28
<i>FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR, 2005 TO FEB. 2009</i>	28
<i>TABLE 23 APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHER AGENCIES (2005 TO FEB 2009)</i>	29
<i>TABLE 24 RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMS (2005 TO FEB. 2009)</i>	29
<i>TABLE 24 (CONTINUED)</i>	30
<i>REGULATORY ISSUES (CONTINUED)</i>	31

CHAPTER FIVE: CLASSIFICATION OF DRUG PRODUCTS BASED ON DRUG DELIVERY TYPE	32
SUSTAINED-RELEASE ORAL DOSAGE FORMS	32
<i>TABLE 25 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE ORAL DOSAGE FORMS</i>	32
<i>TABLE 25 (CONTINUED)</i>	33
SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS	34
<i>TABLE 26 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS</i>	34
SUSTAINED-RELEASE TOPICAL DOSAGE FORMS	35
<i>TABLE 27 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS</i>	35
PRODRUGS	35
<i>TABLE 28 MAJOR SUPPLIERS AND MANUFACTURERS OF PRODRUGS</i>	35
<i>TABLE 28 (CONTINUED)</i>	36
IMPLANTS AND IUDS	36
<i>TABLE 29 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS</i>	36
TRANSDERMAL DRUG DELIVERY SYSTEMS	36
<i>TABLE 30 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS</i>	36
<i>TABLE 30 (CONTINUED)</i>	37
LIPOSOMES	38
<i>TABLE 31 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES</i>	38
NANOPARTICLES	38
<i>TABLE 32 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES</i>	38
POLYMERS.....	39

<i>TABLE 33 MAJOR SUPPLIERS AND MANUFACTURERS OF</i>	
<i>POLYMERS</i>	39
<i>MONOCLONAL ANTIBODIES</i>	40
<i>TABLE 34 MAJOR SUPPLIERS AND MANUFACTURERS OF</i>	
<i>MONOCLONAL ANTIBODIES</i>	40
<i>PEGYNOLOGY</i>	41
<i>TABLE 35 MAJOR SUPPLIERS AND MANUFACTURERS OF</i>	
<i>PEGNOLOGY</i>	41
<i>BUCCAL DRUG DELIVERY SYSTEMS</i>	41
<i>TABLE 36 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL</i>	
<i>DRUG DELIVERY SYSTEMS</i>	41
<i>RECTAL DRUG DELIVERY SYSTEMS</i>	42
<i>TABLE 37 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL</i>	
<i>DRUG DELIVERY SYSTEMS</i>	42
<i>VAGINAL DRUG DELIVERY SYSTEMS</i>	42
<i>TABLE 38 MAJOR SUPPLIERS AND MANUFACTURERS OF</i>	
<i>VAGINAL DRUG DELIVERY SYSTEMS</i>	42
<i>TABLE 7 (CONTINUED)</i>	43
<i>OCULAR DRUG DELIVERY SYSTEMS</i>	43
<i>TABLE 39 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR</i>	
<i>DRUG DELIVERY SYSTEMS</i>	43
<i>TABLE 39 (CONTINUED)</i>	44
<i>INHALATION SYSTEMS</i>	44
<i>TABLE 40 MAJOR SUPPLIERS AND MANUFACTURERS OF</i>	
<i>INHALTION SYSTEMS</i>	44
<i>TABLE 40 (CONTINUED)</i>	45
CHAPTER SIX: INDUSTRY STRUCTURE.....	46
<i>SUSTAINED-RELEASE DOSAGE FORMS</i>	46
<i>SUSTAINED-RELEASE ORAL DOSAGE FORM</i>	46
<i>TABLE 41 SHARES OF MANUFACTURERS/SUPPLIERS FOR</i>	
<i>SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2008 (%)</i>	46
<i>FIGURE 2 SHARES OF MANUFACTURERS/SUPPLIERS OF</i>	
<i>SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2008 (%)</i>	47
<i>SUSTAINED-RELEASE INJECTABLE DOSAGE FORM</i>	48
<i>TABLE 42 SHARES OF MANUFACTURERS/SUPPLIERS FOR</i>	
<i>SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2008 (%)</i>	48
<i>FIGURE 3 SHARES OF MANUFACTURERS/SUPPLIERS OF</i>	
<i>SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2008 (%)</i>	48
<i>SUSTAINED-RELEASE TOPICAL DOSAGE FORM</i>	49
<i>TABLE 43 SHARES OF MANUFACTURERS/SUPPLIERS FOR</i>	
<i>SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2008 (%)</i>	49
<i>FIGURE 4 SHARES OF MANUFACTURERS/SUPPLIERS OF</i>	
<i>SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2008 (%)</i>	49
<i>PRODRUGS</i>	50

<i>TABLE 44 SHARES OF MANUFACTURERS/SUPPLIERS FOR PRODRUGS, 2008 (%).....</i>	<i>50</i>
<i>FIGURE 5 SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS, 2008 (%).....</i>	<i>50</i>
<i>IMPLANTS AND IUDS</i>	<i>51</i>
<i>TABLE 45 SHARES OF MANUFACTURERS FOR IMPLANTS AND IUDS, 2008 (%).....</i>	<i>51</i>
<i>FIGURE 6 SHARES OF MANUFACTURERS OF IMPLANTS AND IUDS, 2008 (%).....</i>	<i>51</i>
<i>TRANSDERMAL DRUG DELIVERY SYSTEMS</i>	<i>52</i>
<i>TABLE 46 SHARES OF MANUFACTURERS/SUPPLIERS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, 2008 (%).....</i>	<i>52</i>
<i>FIGURE 7 SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2008 (%).....</i>	<i>52</i>
<i>TARGETED DRUG DELIVERY SYSTEMS.....</i>	<i>53</i>
<i>LIPOSOMES</i>	<i>53</i>
<i>TABLE 47 SHARES OF MANUFACTURERS/SUPPLIERS FOR LIPOSOMES, 2008 (%).....</i>	<i>53</i>
<i>FIGURE 8 SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2008 (%).....</i>	<i>53</i>
<i>NANOPARTICLES</i>	<i>54</i>
<i>TABLE 48 SHARES OF MANUFACTURERS/SUPPLIERS FOR NANOPARTICLES, 2008 (%).....</i>	<i>54</i>
<i>FIGURE 9 SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2008 (%).....</i>	<i>54</i>
<i>POLYMERS.....</i>	<i>55</i>
<i>TABLE 49 SHARES OF MANUFACTURERS/SUPPLIERS FOR POLYMERS, 2008 (%).....</i>	<i>55</i>
<i>FIGURE 10 SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2008 (%).....</i>	<i>55</i>
<i>MONOCLONAL ANTIBODIES</i>	<i>56</i>
<i>TABLE 50 SHARES OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2008 (%).....</i>	<i>56</i>
<i>FIGURE 11 SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2008 (%).....</i>	<i>56</i>
<i>PEGNOLOGY.....</i>	<i>57</i>
<i>TABLE 51 SHARES OF MANUFACTURERS/SUPPLIERS FOR PEGNOLOGY, 2008 (%)</i>	<i>57</i>
<i>FIGURE 12 SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2008 (%)</i>	<i>57</i>
<i>TRANSMUCOSAL DRUG DELIVERY SYSTEMS.....</i>	<i>58</i>
<i>BUCCAL DRUG DELIVERY SYSTEMS.....</i>	<i>58</i>
<i>TABLE 52 SHARES OF MANUFACTURERS/SUPPLIERS FOR BUCCAL DRUG DELIVERY SYSTEMS, 2008 (%).....</i>	<i>58</i>

<i>FIGURE 13 SHARES OF MANUFACTURERS/ SUPPLIERS OF BUCCAL DRUG DELIVERY SYSTEMS, 2008 (%)</i>	58
RECTAL DRUG DELIVERY SYSTEMS.....	59
<i>TABLE 53 SHARES OF MANUFACTURERS/ SUPPLIERS FOR RECTAL DRUG DELIVERY SYSTEMS, 2008 (%)</i>	59
<i>FIGURE 14 SHARES OF MANUFACTURERS/ SUPPLIERS OF RECTAL DRUG DELIVERY SYSTEMS, 2008 (%)</i>	59
VAGINAL DRUG DELIVERY SYSTEMS	60
<i>TABLE 54 SHARES OF MANUFACTURERS/ SUPPLIERS FOR VAGINAL DRUG DELIVERY SYSTEMS, 2008 (%)</i>	60
<i>FIGURE 15 SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL DRUG DELIVERY SYSTEMS, 2008 (%)</i>	60
OCULAR DRUG DELIVERY SYSTEMS.....	61
<i>TABLE 55 SHARES OF MANUFACTURERS/ SUPPLIERS FOR OCULAR DRUG DELIVERY SYSTEMS, 2008 (%)</i>	61
<i>FIGURE 16 SHARES OF MANUFACTURERS/ SUPPLIERS OF OCULAR DRUG DELIVERY SYSTEMS, 2008 (%)</i>	61
INHALATION SYSTEMS.....	62
<i>TABLE 56 SHARES OF MANUFACTURERS/ SUPPLIERS OF INHALATION SYSTEMS, 2008 (%)</i>	62
<i>FIGURE 17 SHARES OF MANUFACTURERS/ SUPPLIERS OF INHALATION SYSTEMS, 2008 (%)</i>	62
Inhalation Systems (Continued)	63
 CHAPTER SEVEN: DEMAND AND USE	64
OVERALL DRUG DELIVERY MARKET.....	64
FACTORS AFFECTING THE DRUG DELIVERY TECHNOLOGY MARKET.....	65
PATENT EXPIRATION.....	65
<i>TABLE 57 DRUGS WHICH LOST THEIR PATENTS IN 2008</i>	65
<i>TABLE 58 DRUGS WHICH WILL LOSE THEIR PATENTS IN 2009</i>	66
DEMAND FOR NEW DRUG DELIVERY TECHNOLOGIES.....	66
POOR EFFICACY OF CERTAIN DRUGS.....	66
COMPETITION.....	66
CHALLENGES FOR DRUG DELIVERY COMPANIES.....	67
DEMANDS AND TRENDS.....	67
 CHAPTER EIGHT: MARKET ANALYSIS.....	68
<i>TABLE 59 GLOBAL SALES OF DRUG DELIVERY PRODUCTS, THROUGH 2014 (\$ BILLIONS)</i>	68
<i>FIGURE 18 GLOBAL SALES OF DRUG DELIVERY SYSTEMS, 2007- 2014 (\$ BILLIONS)</i>	69
<i>TABLE 60 MARKET SHARE OF DRUG DELIVERY PRODUCTS, 2008 (%)</i>	69
<i>FIGURE 19 MARKET SHARE OF DRUG DELIVERY SYSTEM, 2008 (%)</i>	70

SUSTAINED-RELEASE ORAL DOSAGE FORMS	70
MARKET SIZE	71
<i>TABLE 61 GLOBAL SALES OF SUSTAINED-RELEASE ORAL</i>	
<i>DOSAGE FORMS, THROUGH 2014 (\$ MILLIONS)</i>	71
<i>FIGURE 20 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE ORAL</i>	
<i>DOSAGE FORMS, 2007-2014 (\$ MILLIONS)</i>	72
MARKET OVERVIEW	72
SUSTAINED-RELEASE INJECTABLE DOSAGE FORM.....	73
MARKET SIZE	74
<i>TABLE 62 GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE</i>	
<i>DOSAGE FORMS, THROUGH 2014 (\$ MILLIONS)</i>	74
<i>FIGURE 21 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE</i>	
<i>INJECTABLE DOSAGE FORMS, 2007-2014 (\$ MILLIONS)</i>	75
MARKET OVERVIEW	75
SUSTAINED-RELEASE TOPICAL DOSAGE FORMS	76
MARKET SIZE	76
<i>TABLE 63 GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL</i>	
<i>DOSAGE FORMS, THROUGH 2014 (\$ MILLIONS)</i>	76
<i>FIGURE 22 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE</i>	
<i>TOPICAL DOSAGE FORMS, 2007-2014 (\$ MILLIONS)</i>	77
MARKET OVERVIEW	77
PRODRUGS	78
MARKET SIZE	78
<i>TABLE 64 TOTAL GLOBAL SALES OF PRODRUGS, THROUGH 2014</i>	
<i>(\$ MILLIONS)</i>	79
<i>FIGURE 23 GLOBAL SALES OF PRODRUGS, 2007-2014 (\$ MILLIONS)</i>	79
MARKET OVERVIEW	79
IMPLANTS AND IUDS	80
MARKET SIZE	80
<i>TABLE 65 GLOBAL SALES OF IMPLANTS AND IUDS, THROUGH</i>	
<i>2014 (\$ MILLIONS)</i>	81
<i>FIGURE 24 TOTAL GLOBAL SALES OF IMPLANTS AND IUDS, 2007-</i>	
<i>2014 (\$ MILLIONS)</i>	81
MARKET OVERVIEW	81
TRANSDERMAL DRUG DELIVERY	82
MARKET SIZE	82
<i>TABLE 66 GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY</i>	
<i>SYSTEMS, THROUGH 2014 (\$ MILLIONS)</i>	83
<i>FIGURE 25 TOTAL GLOBAL SALES OF TRANSDERMAL DRUG</i>	
<i>DELIVERY SYSTEMS, 2007-2014 (\$ MILLIONS)</i>	83
MARKET OVERVIEW	83
LIPOSOMES DRUG DELIVERY	84
MARKET SIZE	84

<i>TABLE 67 GLOBAL SALES OF LIPOSOMES, THROUGH 2014 (\$ MILLIONS)</i>	85
<i>FIGURE 26 TOTAL GLOBAL SALES OF LIPOSOMES, 2007-2014 (\$ MILLIONS)</i>	85
MARKET OVERVIEW.....	85
NANOPARTICLES.....	86
MARKET SIZE.....	86
<i>TABLE 68 GLOBAL SALES OF NANOPARTICLES, THROUGH 2014 (\$ MILLIONS)</i>	87
<i>FIGURE 27 GLOBAL SALES OF NANOPARTICLES, 2007-2014 (\$ MILLIONS)</i>	87
MARKET OVERVIEW.....	87
POLYMERS.....	88
MARKET SIZE.....	88
<i>TABLE 69 GLOBAL SALES OF POLYMERS, THROUGH 2014 (\$ MILLIONS)</i>	88
<i>FIGURE 28 GLOBAL SALES OF POLYMERS, 2007-2014 (\$ MILLIONS)</i>	89
MARKET OVERVIEW.....	89
PEGYLATED DRUG DELIVERY.....	90
MARKET SIZE.....	90
<i>TABLE 70 GLOBAL SALES OF PEGYLATED DRUG DELIVERY, THROUGH 2014 (\$ MILLIONS)</i>	90
<i>FIGURE 29 TOTAL GLOBAL SALES OF PEGYLATED DRUG DELIVERY, 2007-2014 (\$ MILLIONS)</i>	91
MARKET OVERVIEW.....	91
MONOCLONAL ANTIBODIES.....	92
MARKET SIZE.....	92
<i>TABLE 71 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2014 (\$ MILLIONS)</i>	92
<i>FIGURE 30 TOTAL GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2007-2014 (\$ MILLIONS)</i>	93
MARKET OVERVIEW.....	93
BUCCAL DRUG DELIVERY.....	94
MARKET SIZE.....	94
<i>TABLE 72 GLOBAL SALES OF BUCCAL DRUG DELIVERY, THROUGH 2014 (\$ MILLIONS)</i>	94
<i>FIGURE 31 TOTAL GLOBAL SALES OF BUCCAL DRUG DELIVERY, 2007-2014 (\$ MILLIONS)</i>	95
MARKET OVERVIEW.....	95
RECTAL DRUG DELIVERY.....	96
MARKET SIZE.....	96
<i>TABLE 73 GLOBAL SALES OF RECTAL DRUG DELIVERY, THROUGH 2014 (\$ MILLIONS)</i>	96

<i>FIGURE 32 TOTAL GLOBAL SALES OF RECTAL DRUG DELIVERY, 2007-2014 (\$ MILLIONS)</i>	97
MARKET OVERVIEW	97
OCULAR DRUG DELIVERY	97
MARKET SIZE	98
<i>TABLE 74 GLOBAL SALES OF OCULAR DRUG DELIVERY, THROUGH 2014 (\$ MILLIONS)</i>	98
<i>FIGURE 33 TOTAL GLOBAL SALES OF OCULAR DRUG DELIVERY, 2007-2014 (\$ MILLIONS)</i>	98
MARKET OVERVIEW	99
VAGINAL DRUG DELIVERY.....	99
MARKET SIZE	99
<i>TABLE 75 GLOBAL SALES OF VAGINAL DRUG DELIVERY, THROUGH 2014 (\$ MILLIONS)</i>	100
<i>FIGURE 34 TOTAL GLOBAL SALES OF VAGINAL DRUG DELIVERY, 2007-2014 (\$ MILLIONS)</i>	100
MARKET OVERVIEW	100
INHALATION DRUG DELIVERY.....	101
MARKET SIZE	101
<i>TABLE 76 GLOBAL SALES OF INHALATION DRUG DELIVERY, THROUGH 2014 (\$ MILLIONS)</i>	101
<i>FIGURE 35 TOTAL GLOBAL SALES OF INHALATION DRUG DELIVERY, 2007-2014 (\$ MILLIONS)</i>	102
MARKET OVERVIEW	102
Market Overview (Continued)	103
CHAPTER NINE: NEW DEVELOPMENTS.....	104
<i>TABLE 77 DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMS</i>	104
<i>TABLE 77 (CONTINUED)</i>	105
<i>TABLE 78 DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS</i>	105
<i>TABLE 78 (CONTINUED)</i>	106
<i>TABLE 79 DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMS</i>	106
<i>TABLE 80 DEVELOPMENTS IN PRODRUGS</i>	106
<i>TABLE 80 (CONTINUED)</i>	107
<i>TABLE 81 DEVELOPMENTS IN IMPLANTS AND IUDS</i>	107
<i>TABLE 81 (CONTINUED)</i>	108
<i>TABLE 82 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS</i>	108
<i>TABLE 82 (CONTINUED)</i>	109
<i>TABLE 83 DEVELOPMENTS IN LIPOSOMAL DELIVERY</i>	109
<i>TABLE 83 (CONTINUED)</i>	110
<i>TABLE 84 DEVELOPMENTS IN PEGYLATED DRUG DELIVERY</i>	110

TABLE 84 (CONTINUED).....	111
TABLE 85 DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY.....	112
TABLE 86 DEVELOPMENTS IN MONOCLONAL ANTIBODIES.....	112
TABLE 86 (CONTINUED).....	113
TABLE 87 DEVELOPMENTS IN BUCCAL DRUG DELIVERY.....	114
TABLE 88 DEVELOPMENTS IN VAGINAL DRUG DELIVERY.....	114
TABLE 89 DEVELOPMENTS IN RECTAL DRUG DELIVERY.....	115
TABLE 90 DEVELOPMENTS IN INHALATION DRUG DELIVERY.....	115
TABLE 90 (CONTINUED).....	116
CHAPTER TEN: MARKET BY THERAPEUTIC AREAS.....	117
MARKET SIZE.....	117
TABLE 91 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN EACH THERAPEUTIC AREA, THROUGH 2014 (\$ BILLIONS).....	117
TABLE 91 (CONTINUED).....	118
FIGURE 36 GLOBAL SALES OF DRUGS TO TREAT LIVER DISEASES, 2007-014 (\$ BILLIONS).....	118
MARKET SHARE.....	119
TABLE 92 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%)......	119
FIGURE 37 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%)......	119
CARDIOVASCULAR DISEASES.....	120
MARKET SIZE.....	120
TABLE 93 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES, THROUGH 2004 (\$ BILLIONS).....	120
FIGURE 38 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES, 2007-2014 (\$ BILLIONS).....	121
ONCOLOGY.....	121
MARKET SIZE.....	121
TABLE 94 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, THROUGH 2014 (\$ BILLIONS).....	122
FIGURE 39 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, 2007-2014 (\$ BILLIONS).....	122
GASTROINTESTINAL.....	122
MARKET SIZE.....	122
TABLE 95 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL DISORDERS, THROUGH 2014 (\$ BILLIONS).....	123
FIGURE 40 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL DISORDERS, 2007-2014 (\$ BILLIONS).....	123
UROLOGY.....	123
MARKET SIZE.....	124
TABLE 96 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, THROUGH 2014 (\$ BILLIONS).....	124

<i>FIGURE 41 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, 2007-2014 (\$ BILLIONS)</i>	124
DIABETES	125
MARKET SIZE	125
<i>TABLE 97 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, THROUGH 2014 (\$ BILLIONS)</i>	125
<i>FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, 2007-2014 (\$ BILLIONS)</i>	126
CENTRAL NERVOUS SYSTEM DISORDER.....	126
MARKET SIZE	126
<i>TABLE 98 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTRAL NERVOUS SYSTEM MARKET, THROUGH 2014 (\$ BILLIONS)</i>	127
<i>FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTRAL NERVOUS SYSTEM MARKET, 2007-2014 (\$ BILLIONS)</i>	127
RESPIRATORY DRUG DELIVERY SYSTEMS.....	127
MARKET SIZE	128
<i>TABLE 99 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RESPIRATORY DISEASES, THROUGH 2014 (\$ BILLIONS)</i>	128
<i>FIGURE 44 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RESPIRATORY DISEASES, 2007-2014 (\$ BILLIONS)</i>	128
INFLAMMATORY DISEASES AND ALLERGY	128
MARKET SIZE	129
<i>TABLE 100 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND ALLERGY, 2007-2014 (\$ BILLIONS)</i>	129
<i>FIGURE 45 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND ALLERGY DISEASES, 2007-2014 (\$ BILLIONS)</i>	129
OPHTHALMOLOGY	130
MARKET SIZE	130
<i>TABLE 101 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH 2014 (\$ BILLIONS)</i>	130
<i>FIGURE 46 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2007-2014 (\$ BILLIONS)</i>	131
VIRAL AND BACTERIAL DISEASES	131
MARKET SIZE	131
<i>TABLE 102 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL DISEASES, THROUGH 2014 (\$ BILLIONS)</i>	132
<i>FIGURE 47 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL DISEASES, 2007-2014 (\$ BILLIONS)</i>	132
HORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY	132
MARKET SIZE	133

<i>TABLE 103 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2014 (\$ BILLIONS)</i>	133
<i>FIGURE 48 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2007-2014 (\$ BILLIONS)</i>	133
OTHERS	134
MARKET SIZE	134
<i>TABLE 104 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS AND TECHNOLOGIES, THROUGH 2014 (\$ BILLIONS)</i>	134
<i>FIGURE 49 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS AND TECHNOLOGIES, 2007-2014 (\$ BILLIONS)</i>	135
CHAPTER ELEVEN: PATENT ANALYSIS	136
PATENTS BY YEAR.....	136
<i>TABLE 105 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2009</i>	137
<i>FIGURE 50 NUMBER OF PATENTS, 2005-2009</i>	137
PATENTS BY TYPE	137
<i>TABLE 106 NUMBER OF PATENTS BY TYPE, 2005-2009</i>	138
<i>FIGURE 51 NUMBER OF PATENTS BY TYPE, 2005-2009</i>	138
<i>FIGURE 52 TOTAL NUMBER OF PATENTS, SHARE BY TYPE, 2005-2009 (%)</i>	139
PATENTS BY COUNTRY	139
<i>TABLE 107 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009</i>	140
<i>FIGURE 53 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009</i>	141
PATENTS BY COMPANY	141
<i>TABLE 108 NUMBER OF PATENTS BY COMPANY, 2005-2009</i>	142
<i>TABLE 108 (CONTINUED)</i>	143
<i>TABLE 108 (CONTINUED)</i>	144
<i>FIGURE 54 NUMBER OF PATENTS BY COMPANY, 2005-2009</i>	145
PATENTS BY ASSIGNEE	145
<i>TABLE 109 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009</i>	145
<i>FIGURE 55 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009</i>	146
CHAPTER TWELVE: COMPANY PROFILES	147
ABBOTT LABORATORIES.....	147
ABRAXIS BIOSCIENCE, INC.	147
AKELA PHARMA	148
AKORN, INC.....	148
ALCON, INC.	149
ALEXION PHARMACEUTICALS	149
ALKERMES, INC.	150
ALLERGAN.....	150

ALPHARX	151
AMGEN	151
ANTIGENICS	151
A P PHARMA.....	152
ASTELLAS PHARMA.....	152
ASTRAZENECA.....	153
ATON PHARMA	153
BARR PHARMACEUTICALS, INC.	153
BAXTER	154
BAYER HEALTHCARE	154
BIOGEN IDEC.....	155
BIOSANTE PHARMACEUTICALS, INC.....	155
BIOVAIL.....	155
BOEHRINGER INGELHEIM	156
BRISTOL MYERS SQUIBB	156
CENTOCOR	157
CEPHALON INC.	157
COLUMBIA LABS.....	157
DIATOS SA	158
EISAI CO.....	158
ELAN.....	159
ENZON	159
EURAND N.V.....	159
GENENTECH	160
GENEREX BIOTECH.....	160
GENZYME	161
GILEAD SCIENCES, INC.....	161
GLAXOSMITHKLINE PLC	161
IMCLONE SYSTEMS.....	162
JOHNSON AND JOHNSON	162
KING PHARMACEUTICALS	163
K.V. PHARMACEUTICAL CO.....	164
LAVIPHARM CORPORATION.....	164
3M COMPANY	165
MERCK & CO.	165
MYLAN LABORATORIES, INC.	166
NEKTAR THERAPEUTICS	166
NOVEN PHARMACEUTICALS, INC.....	167
NOVARTIS AG.....	168
NOVAVAX, INC.....	168
NYCOMED US, INC.....	169
OSI PHARMACEUTICALS, INC.....	169
PAR PHARMACEUTICAL COMPANIES, INC.	170
PDL BIOPHARMA, INC.....	170

PFIZER INC.....	170
QLT, INC.....	171
ROCHE.....	171
SANOFI-AVENTIS.....	172
SCHERING-PLOUGH.....	172
TEVA PHARMACEUTICAL INDUSTRIES, LTD.	173
WATSON PHARMACEUTICALS, INC.....	173
WYETH, INC.	174
APPENDIX: ABBREVIATIONS.....	175
ABBREVIATIONS.....	175
APPENDIX (CONTINUED).....	176